See more : Nippon Paint Holdings Co., Ltd. (NPCPF) Income Statement Analysis – Financial Results
Complete financial analysis of Elite Pharmaceuticals, Inc. (ELTP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elite Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- NS Tool Co., Ltd. (6157.T) Income Statement Analysis – Financial Results
- Raketech Group Holding PLC (RAKE.ST) Income Statement Analysis – Financial Results
- Pacific Software, Inc. (PFSF) Income Statement Analysis – Financial Results
- Shires Income Plc (SHRS.L) Income Statement Analysis – Financial Results
- Fossil Group, Inc. (FOSL) Income Statement Analysis – Financial Results
Elite Pharmaceuticals, Inc. (ELTP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.elitepharma.com
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.63M | 34.16B | 32.26M | 25.38M | 17.99M | 7.57M | 7.46M | 9.64M | 12.50M | 5.02M | 4.60M | 3.40M | 2.42M | 4.27M | 3.34M | 2.27M | 1.41M | 1.14M | 550.70K | 301.48K | 258.25K | 630.31K | 1.20M | 95.25K | 10.32K | 200.00K |
| Cost of Revenue | 30.27M | 17.56B | 17.47M | 13.51M | 10.02M | 4.70M | 3.51M | 5.90M | 4.48M | 3.01M | 3.24M | 2.32M | 1.01M | 2.68M | 2.31M | 1.46M | 1.02M | 831.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 26.36M | 16.59B | 14.80M | 11.87M | 7.98M | 2.87M | 3.95M | 3.74M | 8.01M | 2.00M | 1.37M | 1.09M | 1.41M | 1.59M | 1.04M | 810.26K | 388.61K | 312.59K | 550.70K | 301.48K | 258.25K | 630.31K | 1.20M | 95.25K | 10.32K | 200.00K |
| Gross Profit Ratio | 46.55% | 48.58% | 45.86% | 46.76% | 44.34% | 37.89% | 52.93% | 38.80% | 64.12% | 39.91% | 29.67% | 31.98% | 58.18% | 37.29% | 31.05% | 35.62% | 27.50% | 27.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 6.88M | 6.20B | 4.05M | 5.11M | 5.53M | 7.60M | 9.62M | 8.30M | 12.43M | 14.73M | 3.96M | 975.25K | 1.74M | 1.39M | 794.43K | 3.63M | 5.80M | 6.09M | 4.34M | 2.70M | 2.08M | 2.01M | 1.61M | 1.48M | 1.99M | 1.30M |
| General & Administrative | 6.96M | 5.12B | 4.48M | 3.34M | 3.41M | 3.22M | 2.58M | 2.44M | 3.24M | 3.16M | 2.19M | 1.56M | 1.41M | 876.01K | 1.84M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 340.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.31M | 5.12B | 4.48M | 3.34M | 3.41M | 3.22M | 2.58M | 2.44M | 3.24M | 3.16M | 2.19M | 1.56M | 1.41M | 876.01K | 1.84M | 2.15M | 2.43M | 2.53M | 2.63M | 3.17M | 2.55M | 1.86M | 763.69K | 777.12K | 984.74K | 600.00K |
| Other Expenses | 1.38M | 1.60B | 1.19M | 1.31M | 1.32M | 1.21M | 800.46K | 352.37K | 7.39M | 617.00K | 19.83K | 116.92K | 1.64M | 1.09M | 2.18M | 3.57M | 2.96M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 971.16K | 1.07M | 700.00K |
| Operating Expenses | 15.57M | 12.92B | 9.72M | 9.76M | 10.26M | 12.03M | 13.00M | 11.10M | 16.33M | 18.51M | 6.65M | 2.65M | 3.38M | 2.48M | 2.97M | 7.20M | 8.76M | 9.06M | 6.56M | 5.21M | 4.96M | 4.18M | 2.64M | 2.45M | 3.06M | 2.00M |
| Cost & Expenses | 45.84M | 30.48B | 27.19M | 23.28M | 20.28M | 16.73M | 16.51M | 16.99M | 20.82M | 21.52M | 9.89M | 4.97M | 4.39M | 5.15M | 5.28M | 8.67M | 9.78M | 9.89M | 6.56M | 5.21M | 4.96M | 4.18M | 2.64M | 2.45M | 3.06M | 2.00M |
| Interest Income | 20.92K | 7.45M | 126.00 | 514.00 | 11.98K | 21.46K | 17.51K | 12.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 40.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 588.62K | 1.11M | 191.82K | 259.60K | 355.87K | 369.17K | 335.50K | 238.22K | 280.67K | 287.23K | 899.92K | 392.96K | 654.06K | 1.49M | 261.40K | 252.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.47M | 1.33M | 1.42M | 1.52M | 1.51M | 1.24M | 982.23K | 700.35K | 665.65K | 581.86K | 453.75K | 423.34K | 484.15K | 483.47K | 508.61K | 500.82K | 413.70K | 439.99K | 486.69K | 356.44K | 332.84K | 310.88K | 266.92K | 194.04K | 86.29K | 100.00K |
| EBITDA | 2.58M | 6.43M | 6.27M | 5.93M | -371.88K | -8.34M | -3.40M | 2.88M | -257.15K | 6.12M | -40.11M | 1.95M | -14.40M | -11.91M | -6.02M | -5.85M | -7.84M | -8.31M | -5.52M | -4.56M | -4.37M | -3.24M | -1.18M | -2.16M | -2.96M | -1.75M |
| EBITDA Ratio | 4.56% | 9.63% | 20.16% | 14.30% | -4.24% | -104.12% | -107.76% | -68.78% | -2.05% | -316.83% | -103.51% | -46.34% | -61.14% | -9.43% | -42.66% | -257.10% | -370.42% | -455.13% | -1,042.12% | -1,579.75% | -1,061.29% | -472.54% | -98.14% | -2,265.04% | -28,725.84% | -850.00% |
| Operating Income | 10.79M | 2.03B | 5.07M | 2.10M | -2.29M | -9.16M | -9.05M | -7.36M | -8.32M | -16.51M | -5.28M | -1.56M | -1.97M | -885.76K | -1.94M | -6.39M | -8.37M | -8.75M | -6.01M | -4.91M | -4.70M | -3.55M | -1.44M | -2.35M | -3.05M | -1.80M |
| Operating Income Ratio | 19.05% | 5.93% | 15.72% | 8.29% | -12.70% | -121.01% | -121.35% | -76.32% | -66.54% | -329.14% | -114.83% | -45.93% | -81.11% | -20.76% | -57.90% | -280.91% | -592.09% | -764.77% | -1,090.71% | -1,629.72% | -1,819.75% | -563.57% | -120.43% | -2,468.76% | -29,562.38% | -900.00% |
| Total Other Income/Expenses | -10.33M | 309.87K | 1.23M | 2.04M | 47.06K | -796.64K | 4.33M | 9.30M | 7.11M | 21.72M | -36.27M | 2.70M | -13.58M | -13.00M | -6.12M | -211.27K | -2.54M | -3.06M | -876.41K | -992.62K | -1.81M | -580.48K | -467.71K | -11.98M | 73.17K | 0.00 |
| Income Before Tax | 463.09K | 3.99B | 6.30M | 4.14M | -2.24M | -9.96M | -4.72M | 1.94M | -1.20M | 28.93M | -96.87M | 1.13M | -15.54M | -13.88M | -8.06M | -6.60M | -10.91M | -11.81M | -6.88M | -5.91M | -6.51M | -4.13M | -1.91M | -14.33M | -2.98M | 0.00 |
| Income Before Tax Ratio | 0.82% | 11.67% | 19.54% | 16.33% | -12.44% | -131.54% | -63.27% | 20.17% | -9.63% | 576.77% | -2,105.19% | 33.32% | -641.15% | -325.45% | -240.91% | -290.20% | -772.08% | -1,032.66% | -1,249.86% | -1,958.97% | -2,522.06% | -655.66% | -159.49% | -15,044.14% | -28,853.05% | 0.00% |
| Income Tax Expense | -19.65M | -424.03M | -1.74M | -943.91K | 2.00K | -427.46K | -710.33K | -1.63M | -520.45K | -3.25K | -292.61K | -353.72K | -483.95K | -301.41K | 261.40K | 3.12K | 3.12K | 1.77K | 1.00K | 1.00K | 1.00K | -71.27K | -135.39K | -363.96K | 200.00 | -100.00K |
| Net Income | 20.11M | 4.41B | 8.90M | 5.09M | -2.24M | -9.28M | -3.67M | 3.81M | -683.01K | 28.93M | -96.58M | 1.49M | -15.06M | -13.58M | -8.06M | -6.60M | -13.89M | -11.80M | -6.88M | -5.91M | -6.51M | -4.06M | -1.77M | -13.96M | -2.98M | -1.70M |
| Net Income Ratio | 35.51% | 12.91% | 27.58% | 20.05% | -12.45% | -122.60% | -49.25% | 39.54% | -5.46% | 576.83% | -2,098.83% | 43.72% | -621.19% | -318.38% | -240.91% | -290.34% | -983.15% | -1,031.92% | -1,250.04% | -1,959.30% | -2,522.45% | -644.35% | -148.19% | -14,662.01% | -28,854.99% | -850.00% |
| EPS | 0.02 | 4.35 | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.03 | 0.00 | 0.05 | -0.21 | 0.00 | -0.06 | -0.14 | -0.11 | -0.21 | -0.64 | -0.60 | -0.37 | -0.46 | -0.58 | -0.40 | -0.19 | -1.53 | -0.36 | -0.23 |
| EPS Diluted | 0.02 | 4.35 | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | -0.02 | -0.21 | 0.00 | -0.06 | -0.14 | -0.11 | -0.21 | -0.64 | -0.60 | -0.37 | -0.46 | -0.58 | -0.40 | -0.19 | -1.53 | -0.36 | -0.23 |
| Weighted Avg Shares Out | 1.02B | 1.01B | 1.01B | 943.00M | 832.33M | 814.17M | 796.07M | 838.67M | 673.91M | 591.21M | 459.88M | 349.08M | 259.16M | 100.02M | 75.58M | 32.05M | 21.80M | 19.82M | 18.46M | 12.87M | 11.17M | 10.07M | 9.56M | 9.14M | 8.29M | 7.39M |
| Weighted Avg Shares Out (Dil) | 1.02B | 1.01B | 1.01B | 943.00M | 832.33M | 816.31M | 798.17M | 844.51M | 673.91M | 757.58M | 463.02M | 526.88M | 259.16M | 100.02M | 75.58M | 32.05M | 21.80M | 19.82M | 18.46M | 12.87M | 11.17M | 10.07M | 9.56M | 9.14M | 8.29M | 7.39M |
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2022 Financial Results on August 17, 2021
Elite Pharmaceuticals, Inc.'s (ELTP) CEO Nasrat Hakim on Q4 2021 Results - Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-End Financial Results on June 15, 2021
Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules
Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer
Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports